IL2 and non-small cell lung carcinoma: Currently, a trial (NCT02118415) is taking place to test the efficacy of sequential immunotherapy using autologous NK cells and Hsp70-peptide TKD/IL-2 in patients with NSCLC (stage IIIa, b) after radiotherapy and chemotherapy (Table 1) [164].